Axsome Therapeutics rises on migraine drug trial data

Axsome Therapeutics

24/02/2025 13:59

** Drugmaker Axsome Therapeutics'  AXSM.O  shares rise 1.6%
to $139.98 premarket
    ** AXSM says its drug, Symbravo, met the main goal in a
late-stage trial to treat migraine headaches in patients who
didn't respond well to other treatments
    ** Symbravo is a combination of two medicines, meloxicam and
rizatriptan
    ** In the trial, Symbravo was found to be more effective
than oral CGRP inhibitors in relieving migraine pain, with 47.9%
of patients pain-free within 2 hours, compared with only 1% of
patients who took oral CGRP inhibitors, the company says
    ** Symbravo is not recommended for people with heart
problems, high blood pressure, or kidney disease, or for
pregnant or breastfeeding women
    ** AXSM gained 6.3% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))